Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Organogenesis Holdings Inc. ORGO
$3.11
+$0.25 (7.99%)
На 18:01, 12 мая 2023
Ранг: 2
Ключевые показатели
-
Marketcap
391898122.00000000
-
week52high
6.52
-
week52low
1.80
-
Revenue
450893000
-
P/E TTM
17
-
Beta
1.42847400
-
EPS
0.12000000
-
Last Dividend
0.00000000
-
Next Earnings Date
10 мая 2023 г. в 20:00
Описание компании
Organogenesis Holdings Inc., a regenerative medicine company develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane wound covering in which viable cells growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, and cytokines; NuShield, a wound covering tissue includes both amnion and chorion membranes for spongy/intermediate layer intact; PuraPly , a antimicrobial barrier that enables conformability and fluid drainage; and Novachor, an amniotic membrane wound covering in which viable cells, growth factors/cytokines, and ECM proteins are preserved. Its surgical and sports medicine products comprise NuCel, a dehydrated placental tissue surgically applied to the target tissue to support native healing; ReNu, a cryopreserved suspension used to support healing of soft tissues; and FiberOS and OCMP used as a bone void filler primarily in orthopedic and neurosurgical applications. The company's pipeline products include PuraPly XT and PuraPly MZ to treat chronic, acute, and open wounds; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; and TransCyte, a bioengineered tissue for the treatment of partial thickness burns. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales force and independent agencies. The company was founded in 1985 and is headquartered in Canton, Massachusetts.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| SVB Leerink | Outperform | Outperform | 10 ноя 2021 г. |
| Credit Suisse | Outperform | Outperform | 10 авг 2021 г. |
| SVB Leerink | Outperform | Outperform | 11 мая 2021 г. |
| SVB Leerink | Outperform | Outperform | 17 мар 2021 г. |
| SVB Leerink | Outperform | Outperform | 20 янв 2021 г. |
| BTIG | Neutral | Buy | 10 ноя 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| KATZ MICHAEL W | A | 76382 | 3000 | 21 ноя 2022 г. |
| KATZ MICHAEL W | A | 73382 | 3000 | 18 ноя 2022 г. |
| Grow Brian | D | 0 | 805 | 20 авг 2022 г. |
| Grow Brian | A | 87744 | 805 | 20 авг 2022 г. |
| Leibowitz Arthur S | A | 70854 | 3000 | 12 авг 2022 г. |
| Driscoll Michael Joseph | A | 25547 | 5000 | 12 авг 2022 г. |
| Gillheeney Gary S. | D | 0 | 505050 | 30 июн 2022 г. |
| Gillheeney Gary S. | A | 903292 | 505050 | 30 июн 2022 г. |
| ERANI ALBERT | D | 59248027 | 29669 | 13 июн 2022 г. |
| ERANI ALBERT | D | 59277696 | 331 | 09 июн 2022 г. |
Новостная лента
Why Shares of Organogenesis Holdings Jumped Thursday
The Motley Fool
11 мая 2023 г. в 14:33
Organogenesis said it expects sales to rise between 1% and 3% this year. The company said revenue rose by 10% year over year in the first quarter.
Organogenesis Holdings Inc. (ORGO) Q1 2023 Earnings Call Transcript
Seeking Alpha
10 мая 2023 г. в 23:50
Organogenesis Holdings Inc. (NASDAQ:ORGO ) Q1 2023 Earnings Conference Call May 10, 2023 5:00 PM ET Company Participants Gary Gillheeney - President and CEO Dave Francisco - CFO Conference Call Participants Ryan Zimmerman - BTIG Operator Welcome, ladies and gentlemen to the First Quarter of Fiscal Year 2023 Earnings Conference Call for the Organogenesis Holdings Inc. At this time, all participants have been placed in a listen-only mode. Please note that this conference call is being recorded and that the recording will be available on the company's website for replay shortly.
Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2023 Financial Results on May 10, 2023
GlobeNewsWire
10 апр 2023 г. в 07:30
CANTON, Mass., April 10, 2023 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that first quarter of fiscal year 2023 financial results will be reported after the market closes on Wednesday, May 10th.
Why Shares of Unisys, Organogenesis, and Motorcar Parts of America Fell Today
The Motley Fool
06 мар 2023 г. в 18:29
The S&P SmallCap 600 index dropped all three stocks.
Organogenesis Holdings Inc. (ORGO) Q4 2022 Earnings Call Transcript
Seeking Alpha
01 мар 2023 г. в 22:17
Organogenesis Holdings Inc. (NASDAQ:ORGO ) Q4 2022 Earnings Conference Call March 1, 2023 5:00 PM ET Company Participants Gary Gillheeney - President and Chief Executive Officer Dave Francisco - Chief Financial Officer Conference Call Participants Ryan Zimmerman - BTIG Operator Welcome, ladies and gentlemen to the Fourth Quarter and Fiscal Year 2022 Earnings Conference Call for Organogenesis Holdings Inc. [Operator Instructions] Please note that this conference call is being recorded and that the recording will be available on the company's website for replay shortly. Before we begin, I would like to remind everyone that our remarks today may contain forward-looking statements that are based on the current expectations of management and involve inherent risks and uncertainties that could cause actual results to differ materially from those indicated, including the risks and uncertainties described in the company's filings with the Securities and Exchange Commission, including Item 1A Risk Factors of the company's most recent annual report and its subsequently filed quarterly reports.